We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-2.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.42B
AUM Growth
-$48.5M
Cap. Flow
+$49.9M
Cap. Flow %
3.5%
Top 10 Hldgs %
29.29%
Holding
97
New
3
Increased
35
Reduced
20
Closed
5

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$33.3M
2
PFE icon
Pfizer
PFE
+$22.2M
3
BIIB icon
Biogen
BIIB
+$19.7M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.4M
5
MCK icon
McKesson
MCK
+$14M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.6M
2
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$20.4M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$14M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.94M
5
PHR icon
Phreesia
PHR
+$9.11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
2 Industrials 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
76
DELISTED
ESSA Pharma
EPIX
$4.8M 0.34%
600,000
+340,000
+131% +$5.41M
ANNX icon
77
Annexon
ANNX
$883M
$4.65M 0.33%
250,000
– –
PGNY icon
78
Progyny
PGNY
$2.14B
$4.48M 0.31%
80,000
– –
OSH
79
DELISTED
Oak Street Health, Inc.
OSH
$4.47M 0.31%
105,000
+10,000
+11% +$537K
GTHX
80
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.36M 0.31%
325,000
– –
STXS icon
81
Stereotaxis
STXS
$143M
$4.3M 0.3%
800,000
+115,598
+17% +$872K
ARNA
82
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.57M 0.25%
60,000
– –
OLK
83
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$3.4M 0.24%
+140,000
New +$4.4M
IMCR icon
84
Immunocore
IMCR
$1.73B
$3.34M 0.23%
90,000
– –
IONS icon
85
Ionis Pharmaceuticals
IONS
$9.46B
$2.52M 0.18%
75,000
– –
KYNB
86
Kyntra Bio
KYNB
$28.2M
$2.04M 0.14%
8,000
– –
DCPH
87
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.04M 0.14%
60,000
– –
PVLA
88
Palvella Therapeutics
PVLA
$2.19B
$1.55M 0.11%
3,750
– –
SPRY icon
89
ARS Pharmaceuticals
SPRY
$587M
$1.5M 0.11%
150,000
+50,000
+50% +$1.23M
EPZM
90
DELISTED
Epizyme, Inc
EPZM
$1.36M 0.1%
265,000
– –
INNV icon
91
InnovAge Holding
INNV
$1.48B
$992K 0.07%
150,000
– –
XLRN
92
DELISTED
Acceleron Pharma
XLRN
$756K 0.05%
4,392
-195,608
-98% -$25.6M
BAX icon
93
Baxter International
BAX
$14.4B
– –
-110,000
Closed -$8.86M
LIVN icon
94
LivaNova
LIVN
$4.21B
– –
-10,000
Closed -$841K
REGN icon
95
Regeneron Pharmaceuticals
REGN
$83.2B
– –
-25,000
Closed -$14M
ZLAB icon
96
Zai Lab
ZLAB
$2.65B
– –
-35,000
Closed -$6.2M
INOV
97
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
– –
-600,000
Closed -$20.4M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rhenman & Partners Asset Management held 97 positions worth $1.42B, down 3.3% from $1.47B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $49.9M of net new capital in Q3 2021, opening 3 new positions and adding to 35 existing holdings. Its largest new stake was Privia Health: 240,000 shares worth $5.65M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Acceleron Pharma, an estimated $25.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2021 buy was Privia Health: 240,000 shares worth $5.65M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q3 2021, an estimated $33.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.6M.
  • Rhenman & Partners Asset Management fully exited Inovalon Holdings, Inc. Class A Common Stock in Q3 2021, selling an estimated $20.4M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q3 2021.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 5 in Q3 2021.
  • Rhenman & Partners Asset Management's portfolio value fell 3.3% quarter-over-quarter to $1.42B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.